Drugs in the Pipeline Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression Publish Date August 22, 2018 The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.
